The Phase II AveNEC trial, published in Clinical Cancer Research (February 2025), evaluated avelumab in patients with high-grade neuroendocrine neoplasms (NEN G3) who had progressed after prior chemotherapy. The study found a disease control rate of 15%, with some patients achieving durable responses beyond six months. Median progression-free survival was 1.9 months, and overall survival was 6.6 months, with responders showing a significantly longer survival of 30.2 months. Avelumab was well tolerated, with stable quality of life.
While responses were limited, the findings suggest potential benefit for select patients, reinforcing the need for more effective second-line therapies in high-grade NENs.
For more information: https://lnkd.in/eagkuxcR
